Meet Our Scientific Advisory Board
A group of global experts guiding QABY’s scientific, translational, and clinical strategy.
Dr. Erwan Bezard is a globally renowned neuroscientist recognized for his pioneering research on Parkinson’s disease and related disorders.
His work has transformed the understanding of disease mechanisms and therapeutic approaches, leading numerous translational and biotech initiatives worldwide.
With over 360 scientific publications and ranked among the top 1% most cited neuroscientists globally (Clarivate 2022; h-index 104), Dr. Bezard has significantly advanced knowledge of disease progression, compensatory processes, and treatment strategies for movement disorders.
He founded and directed the Institute of Neurodegenerative Diseases in Bordeaux, uniting preclinical and clinical teams to accelerate translational research. Dr. Bezard is Editor-in-Chief of Neurobiology of Disease and advises major organizations such as the Michael J. Fox Foundation and Parkinson’s UK.
He also serves as CEO and CSO of Motac Neuroscience, co-founder of Treefrog Therapeutics and SE Therapeutics, and holds shares in QABY Biotech.
Dr. Erwan Bezard
INSERM Research Director (DRCE), France
Leading neuroscientist internationally recognized for his groundbreaking research on Parkinson’s disease and related disorders.
Dr. Michael Schlossmacher is a renowned neurologist and physician-scientist celebrated for his groundbreaking contributions to neurodegenerative disease research.
He spearheads a leading research program at the University of Ottawa and co-founded NeuroScent Solutions to develop cutting-edge early diagnostic technologies.
A graduate of the University of Vienna, Dr. Schlossmacher trained with Dr. Dennis Selkoe at Harvard, where he played a key role in the seminal discovery that amyloid-beta (Aβ) peptide is produced and secreted under normal physiological conditions—an insight that transformed Alzheimer’s research globally.
Since 2007, he has directed a research program at the University of Ottawa dedicated to Parkinson’s disease and related dementias.
Additionally, Dr. Schlossmacher leads the Neuroscience Program at the Ottawa Hospital Research Institute and co-founded NeuroScent Solutions, pioneering innovative diagnostic tools like the NeuroScent Card® to measure smell loss and facilitate earlier Parkinson’s disease detection.
Dr. Michael Schlossmacher
Physician-Scientist, University of Ottawa
Dr. Michael Schlossmacher is a neurologist and physician-scientist whose work has shaped modern understanding of Parkinson’s and Alzheimer’s diseases.
Dr. Dominic Walsh
Neuroscientist and Biopharma R&D Leader
Dr. Dominic Walsh is a top 1% neuroscientist known for groundbreaking research in molecular pathology of neurodegenerative diseases.
Dr. Dominic Walsh is a world-renowned neuroscientist with over three decades of research into the molecular pathology of neurodegenerative diseases.
He has authored more than 160 scientific publications, delivered over 100 invited lectures, and is recognized among The World’s Most Influential Scientific Minds (Thomson Reuters, 2014–2016), ranking in the top 1% of neuroscientists globally.
Dominic joined Biogen in 2018, where he led the Alzheimer’s Disease & Dementia Research Unit, and later the Neurodegenerative Diseases Research Unit (NDRU), overseeing discovery through Phase 2 clinical programs until his retirement in 2024.
He continues to serve as a scientific advisor to several biotech and pharmaceutical companies and holds academic appointments at Harvard Medical School, University College London, and Trinity College Dublin..
John McDonough
Executive Chairman, CEO & Industry Leader
Biotech executive with 30+ years of leadership, securing $500M+ in funding and creating $6B+ in market value across several companies.
John McDonough is currently the executive chairman of the board of directors and the chief executive officer at Sunbird Bio, chairman at Cytrellis Biosystems,and founder and president of the Crush Colon Cancer Foundation.
With experience spanning more than 30 years, John is responsible for raising more than $500 million in public and private capital, creating over $6 billion of market value for five different companies.
He has previously served in chief executive officer, senior executive and board member roles at both private and public companies, where he successfully led two IPOs, led the acquisition of five companies, and led mergers and acquisitions with three companies.
